Novavax (NVAX) Tops Q2 EPS by 210c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts NVAX Hot Sheet
Price: $9.68 +1.57%
Financial Fact:
Basic and diluted net loss per share: -0.24
Today's EPS Names:
FUSE, INM, TRI, More
Financial Fact:
Basic and diluted net loss per share: -0.24
Today's EPS Names:
FUSE, INM, TRI, More
Join SI Premium – FREE
Novavax (NASDAQ: NVAX) reported Q2 EPS of $0.58, $2.10 better than the analyst estimate of ($1.52). Revenue for the quarter came in at $424.43 million versus the consensus estimate of $237.39 million.
For earnings history and earnings-related data on Novavax (NVAX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ultragenyx Pharma (RARE) Misses Q3 EPS by 6c; Offers Guidance
- Spyre Therapeutics, Inc. (SYRE) Misses Q3 EPS by 16c
- Tarsus Pharmaceuticals, Inc. (TARS) Misses Q3 EPS by 1293c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
